Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry

  1. Valeria Ramaglia  Is a corresponding author
  2. Salma Sheikh-Mohamed
  3. Karen Legg
  4. Calvin Park
  5. Olga L Rojas
  6. Stephanie Zandee
  7. Fred Fu
  8. Olga Ornatsky
  9. Eric C Swanson
  10. David Pitt
  11. Alexandre Prat
  12. Trevor D McKee
  13. Jennifer L Gommerman
  1. University of Toronto, Canada
  2. Yale School of Medicine, United States
  3. Université de Montreal, Canada
  4. University Health Network, Canada
  5. Fluidigm Inc, Canada
  6. Université de Montréal, Canada

Abstract

Multiple Sclerosis (MS) is characterized by demyelinated and inflammatory lesions in the brain and spinal cord that are highly variable in terms of cellular content. Here we used imaging mass cytometry (IMC) to enable the simultaneous imaging of 15+ proteins within staged MS lesions. To test the potential for IMC to discriminate between different types of lesions, we selected a case with severe rebound MS disease activity after natalizumab cessation. With post-acquisition analysis pipelines we were able to: (1) Discriminate demyelinating macrophages from the resident microglial pool; (2) Determine which types of lymphocytes reside closest to blood vessels; (3) Identify multiple subsets of T and B cells, and (4) Ascertain dynamics of T cell phenotypes vis-à-vis lesion type and location. We propose that IMC will enable a comprehensive analysis of single-cell phenotypes, their functional states and cell-cell interactions in relation to lesion morphometry and demyelinating activity in MS patients.

Data availability

All data generated and analysed during this study are included in the manuscript and supporting files. Source data file has been provided for Figure 7.

Article and author information

Author details

  1. Valeria Ramaglia

    Department of Immunology, University of Toronto, Toronto, Canada
    For correspondence
    v.ramaglia@utoronto.ca
    Competing interests
    Valeria Ramaglia, received a consulting honorarium from EMD Serono.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9401-5988
  2. Salma Sheikh-Mohamed

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  3. Karen Legg

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  4. Calvin Park

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    No competing interests declared.
  5. Olga L Rojas

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  6. Stephanie Zandee

    Department of Neuroscience, Université de Montreal, Montreal, Canada
    Competing interests
    No competing interests declared.
  7. Fred Fu

    STTARR Innovation center, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  8. Olga Ornatsky

    Fluidigm Inc, Markham, Canada
    Competing interests
    Olga Ornatsky, is an employee of Fluidigm Inc.
  9. Eric C Swanson

    Fluidigm Inc, Markham, Canada
    Competing interests
    Eric C Swanson, is an employee of Fluidigm Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8454-1207
  10. David Pitt

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6407-9542
  11. Alexandre Prat

    Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montreal, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6188-0580
  12. Trevor D McKee

    STTARR Innovation center, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  13. Jennifer L Gommerman

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    Jennifer L Gommerman, is a consultant for Roche (Canada) and currently holds grants with Novartis, EMD Serono, and Roche.

Funding

National Multiple Sclerosis Society (RR-1602-07777)

  • Valeria Ramaglia

Multiple Sclerosis Society of Canada

  • Jennifer L Gommerman

Multiple Sclerosis Society of Canada

  • Alexandre Prat

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Isaac M Chiu, Harvard Medical School, United States

Ethics

Human subjects: This work included the use of post-mortem brain tissue. Written consent for post-mortem donation of the CNS to research from the MS donor was obtained (ethics committee approval number BH.07.001).Ethical approval for the use of post-mortem brain tissue from the control donor of the Netherlands Brain Bank was obtained (VU Medical Center ethic committee approval Reference number 2009/148)

Version history

  1. Received: April 29, 2019
  2. Accepted: August 1, 2019
  3. Accepted Manuscript published: August 1, 2019 (version 1)
  4. Version of Record published: August 23, 2019 (version 2)

Copyright

© 2019, Ramaglia et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,635
    views
  • 846
    downloads
  • 57
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Valeria Ramaglia
  2. Salma Sheikh-Mohamed
  3. Karen Legg
  4. Calvin Park
  5. Olga L Rojas
  6. Stephanie Zandee
  7. Fred Fu
  8. Olga Ornatsky
  9. Eric C Swanson
  10. David Pitt
  11. Alexandre Prat
  12. Trevor D McKee
  13. Jennifer L Gommerman
(2019)
Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry
eLife 8:e48051.
https://doi.org/10.7554/eLife.48051

Share this article

https://doi.org/10.7554/eLife.48051

Further reading

    1. Immunology and Inflammation
    Xiaozhuo Yu, Wen Zhou ... Yanhong Ji
    Research Article

    The evolutionary conservation of non-core RAG regions suggests significant roles that might involve quantitative or qualitative alterations in RAG activity. Off-target V(D)J recombination contributes to lymphomagenesis and is exacerbated by RAG2’ C-terminus absence in Tp53−/− mice thymic lymphomas. However, the genomic stability effects of non-core regions from both Rag1c/c and Rag2c/c in BCR-ABL1+ B-lymphoblastic leukemia (BCR-ABL1+ B-ALL), the characteristics, and mechanisms of non-core regions in suppressing off-target V(D)J recombination remain unclear. Here, we established three mouse models of BCR-ABL1+ B-ALL in mice expressing full-length RAG (Ragf/f), core RAG1 (Rag1c/c), and core RAG2 (Rag2c/c). The Ragc/c (Rag1c/c and Rag2c/c) leukemia cells exhibited greater malignant tumor characteristics compared to Ragf/f cells. Additionally, Ragc/c cells showed higher frequency of off-target V(D)J recombination and oncogenic mutations than Ragf/f. We also revealed decreased RAG cleavage accuracy in Ragc/c cells and a smaller recombinant size in Rag1c/c cells, which could potentially exacerbate off-target V(D)J recombination in Ragc/c cells. In conclusion, these findings indicate that the non-core RAG regions, particularly the non-core region of RAG1, play a significant role in preserving V(D)J recombination precision and genomic stability in BCR-ABL1+ B-ALL.

    1. Cell Biology
    2. Immunology and Inflammation
    Kevin Portmann, Aline Linder, Klaus Eyer
    Research Article

    Cytokine polyfunctionality is a well-established concept in immune cells, especially T cells, and their ability to concurrently produce multiple cytokines has been associated with better immunological disease control and subsequent effectiveness during infection and disease. To date, only little is known about the secretion dynamics of those cells, masked by the widespread deployment of mainly time-integrated endpoint measurement techniques that do not easily differentiate between concurrent and sequential secretion. Here, we employed a single-cell microfluidic platform capable of resolving the secretion dynamics of individual PBMCs. To study the dynamics of poly-cytokine secretion, as well as the dynamics of concurrent and sequential polyfunctionality, we analyzed the response at different time points after ex vivo activation. First, we observed the simultaneous secretion of cytokines over the measurement time for most stimulants in a subpopulation of cells only. Second, polyfunctionality generally decreased with prolonged stimulation times and revealed no correlation with the concentration of secreted cytokines in response to stimulation. However, we observed a general trend towards higher cytokine secretion in polyfunctional cells, with their secretion dynamics being distinctly different from mono-cytokine-secreting cells. This study provided insights into the distinct secretion behavior of heterogenous cell populations after stimulation with well-described agents and such a system could provide a better understanding of various immune dynamics in therapy and disease.